BridgeMD
New treatment option for Ischemic Stroke
Official title Study of Tiprogrel in the Treatment of High-risk Patients with Acute Ischemic Cerebrovascular Events (THRIVE).
ClinicalTrials.gov ID: NCT06601127
What this study is testing
What is Tiprogrel?
Tiprogrel is an investigational medicine, given as an once-daily, being studied as a potential treatment for ischemic stroke.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is designed to evaluate efficacy and safety of tiprogrel in the treatment of patients with acute ischemic cerebrovascular events.
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 40 and older
You may be able to join if
- Age ≥ 40 years
- Acute Minor Ischaemic Stroke：AIS is defined as acute onset of neurological deficit attributed to focal brain ischaemia, NIHSS ≤5, and either of the...
- Acute single infarction with ≥50% stenosis of a major intracranial or extracranial artery.
- Acute multiple infarctions attributed to large-artery atherosclerosis, including non-stenotic vulnerable plaques. TIA with high risk of stroke: ABCD2...
You likely can't join if
- Bleeding or other pathological brain disorders including malformation, tumor, abscess or other major non-ischemic brain disease on baseline head CT...
- Isolated or pure sensory symptoms, isolated visual changes, or isolated dizziness/vertigo without evidence of acute infarction on baseline head CT or...
- Preceding mRS\> 2
- Contraindication to anti-platelet therapy
- Clear indication for anticoagulation
- Two or more antiplatelet drugs have been used continuously for ≥3 days before enrollment.
See the full eligibility criteria
- Age ≥ 40 years
- Acute Minor Ischaemic Stroke：AIS is defined as acute onset of neurological deficit attributed to focal brain ischaemia, NIHSS ≤5, and either of the following imaging characteristics:
- Acute single infarction with ≥50% stenosis of a major intracranial or extracranial artery.
- Acute multiple infarctions attributed to large-artery atherosclerosis, including non-stenotic vulnerable plaques. TIA with high risk of stroke: ABCD2 score ≥ 6 at the time of randomization, and the following imaging...
- Bleeding or other pathological brain disorders including malformation, tumor, abscess or other major non-ischemic brain disease on baseline head CT or MRI
- Isolated or pure sensory symptoms, isolated visual changes, or isolated dizziness/vertigo without evidence of acute infarction on baseline head CT or MRI.
- Preceding mRS\> 2
- Contraindication to anti-platelet therapy
- Clear indication for anticoagulation
- Two or more antiplatelet drugs have been used continuously for ≥3 days before enrollment.
- Used heparin or oral anticoagulant drugs within 10 days before enrollment
- Undergone intravenous or arterial thrombolysis and mechanical thrombectomy within 24 hours before enrollment
- History of intracranial hemorrhage or amyloid angiopathy
- History of aneurysm
- Diagnosis or suspicious diagnosis of acute coronary syndrome
- History of asthma
- High-risk for bradyarrhythmia
- Anticipated requirement for long-term (\>5 days) non-steroidal anti-inflammatory drugs or NSAIDs within the 8th day of randomization
- History of gastrointestinal bleeding within 3 months before enrollment or major surgery within 30 days
- Iatrogenic causes of minor stroke or TIA
- Planned or likely revascularization within the next 3 months, scheduled for surgery or treatment treatment requiring study drug cessation
- Severe non-cardiovascular comorbidity with life expectancy \< 3 months
- Women of childbearing age who have not taken effective contraceptive measures and have a positive pregnancy test record, as well as women who are pregnant or breastfeeding
- Currently receiving an experimental drug or device
- Participation in another clinical study with an experimental product during the last 30 days
- Inability to understand and/or follow research procedures due to mental, cognitive, or emotional disorders
- Hemoglobin \<90g/L %
- Permanent hypertension
- people who were judged by the investigator to be unsuitable for this clinical study
The study team makes the final eligibility decision.
Where it's taking place
- Shenyang, Liaoning, China
- Beijing, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 40 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shenyang, Liaoning, China; Beijing, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.